Margarita Del Val

Margarita Del Val

Auto-generated profile, based on publicly available information

Margarita Del Val

Centro de Biologia Molecular Severo Ochoa - CSIC/UAM

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2005 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
LSLoredana Saveanu
Loredana Saveanu
OCOliver Carroll
Oliver Carroll
VLVivian Lindo
Vivian Lindo
MVMargarita Del Val
Margarita Del Val
DLDaniel López
Daniel López
Peter Van EndertPeter Van Endert
Peter Van Endert

1 September 1991 in Cell
Verified
Journal Article
Closed access
MVMargarita Del Val
Margarita Del Val
HSHans-Jürgen Schlicht
Hans-Jürgen Schlicht
TRThomas Ruppert
Thomas Ruppert
MRMatthias J. Reddehase
Matthias J. Reddehase
UKUlrich H. Koszinowski
Ulrich H. Koszinowski

1 September 1992 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MVM del Val
M del Val
HHH Hengel
H Hengel
HHH Häcker
H Häcker
UHU Hartlaub
U Hartlaub
TRT Ruppert
T Ruppert
UKU H Koszinowski
U H Koszinowski
Selective expression of murine cytomegalovirus (MCMV) immediate-early (IE) genes leads to the presentation by the major histocompatibility complex (MHC) class I molecule Ld of a peptide derived from MCMV IE protein pp89 (Reddehase, M.J., J. B. Rothbard, and U.H. Koszinowski. 1989. Nature (Lond.). 337:651). Characterization of endogenous antigenic peptides identified the pp89 peptide as the nonapeptide 168YPHFMPTNL176 (del Val, M., H.-J. Schlicht, T. Ruppert, M.J. Reddehase, and U.H. Koszinowski. 1991. Cell. 66:1145). Subsequent expression of MCMV early genes prevents presentation of pp89 (del Val, M., K. Münch, M.J. Reddehase, and U.H. Koszinowski. 1989. Cell. 58:305). We report on the mechanism by which MCMV early genes interfere with antigen presentation. Expression of the IE promoter-driven bacterial gene lacZ by recombinant MCMV subjected antigen presentation of beta-galactosidase to the same control and excluded antigen specificity. The Ld-dependent presence of naturally processed antigenic peptides also in nonpresenting cells located the inhibitory function subsequent to the step of antigen processing. The finding that during the E phase of MCMV gene expression the MHC class I heavy chain glycosylation remained in an Endo H-sensitive form suggested a block within the endoplasmic reticulum/cis-Golgi compartment. The failure to present antigenic peptides was explained by a general retention of nascent assembled trimolecular MHC class I complexes. Accordingly, at later stages of infection a significant decrease of surface MHC class I expression was seen, whereas other membrane glycoproteins remained unaffected. Thus, MCMV E genes endow this virus with an effective immune evasion potential. These results also indicate that the formation of the trimolecular complex of MHC class I heavy chain, beta 2-microglobulin, and the finally trimmed peptide is completed before entering the medial-Golgi compartment.

6 February 2012 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MBMaria Buxadé
Maria Buxadé
GLGiulia Lunazzi
Giulia Lunazzi
JMJordi Minguillón
Jordi Minguillón
Salvador IborraSalvador Iborra
Salvador Iborra
RBRosa Berga-Bolaños
Rosa Berga-Bolaños
CLCristina López-Rodríguez
Cristina López-Rodríguez
Toll-like receptors (TLRs) engage networks of transcriptional regulators to induce genes essential for antimicrobial immunity. We report that NFAT5, previously characterized as an osmostress responsive factor, regulates the expression of multiple TLR-induced genes in macrophages independently of osmotic stress. NFAT5 was essential for the induction of the key antimicrobial gene Nos2 (inducible nitric oxide synthase [iNOS]) in response to low and high doses of TLR agonists but is required for Tnf and Il6 mainly under mild stimulatory conditions, indicating that NFAT5 could regulate specific gene patterns depending on pathogen burden intensity. NFAT5 exhibited two modes of association with target genes, as it was constitutively bound to Tnf and other genes regardless of TLR stimulation, whereas its recruitment to Nos2 or Il6 required TLR activation. Further analysis revealed that TLR-induced recruitment of NFAT5 to Nos2 was dependent on inhibitor of κB kinase (IKK) β activity and de novo protein synthesis, and was sensitive to histone deacetylases. In vivo, NFAT5 was necessary for effective immunity against Leishmania major, a parasite whose clearance requires TLRs and iNOS expression in macrophages. These findings identify NFAT5 as a novel regulator of mammalian anti-pathogen responses.

1 July 1989 in Cell
Verified
Journal Article
Closed access
MVMargarita Del Val
Margarita Del Val
KMKonrad Münch
Konrad Münch
MRMatthias J. Reddehase
Matthias J. Reddehase
UKUlrich H. Koszinowski
Ulrich H. Koszinowski

9 February 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JNJudith Navarro
Judith Navarro
BGBeatriz Gozalbo-López
Beatriz Gozalbo-López
AMAndrea C. Méndez
Andrea C. Méndez
FDFrançoise Dantzer
Françoise Dantzer
VSValérie Schreiber
Valérie Schreiber
JYJose Yelamos
Jose Yelamos
The maintenance of T-cell homeostasis must be tightly regulated. Here, we have identified a coordinated role of Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 in maintaining T-lymphocyte number and function. Mice bearing a T-cell specific deficiency of PARP-2 in a PARP-1-deficient background showed defective thymocyte maturation and diminished numbers of peripheral CD4+ and CD8+ T-cells. Meanwhile, peripheral T-cell number was not affected in single PARP-1 or PARP-2-deficient mice. T-cell lymphopenia was associated with dampened in vivo immune responses to synthetic T-dependent antigens and virus, increased DNA damage and T-cell death. Moreover, double-deficiency in PARP-1/PARP-2 in T-cells led to highly aggressive T-cell lymphomas with long latency. Our findings establish a coordinated role of PARP-1 and PARP-2 in T-cell homeostasis that might impact on the development of PARP-centred therapies.